Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Current Drug Therapy

Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes

Abhayjit Singh, MD and Leslie S. Cho, MD
Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058
Abhayjit Singh
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie S. Cho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, with low-density lipoprotein (LDL) cholesterol being a causative risk factor. Though statins have a decades-long track record of efficacy and safety, nonstatin agents may be used to reduce LDL cholesterol as an adjunct or alternative to statin therapy. Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease. This review addresses the indications, evidence, and important prescribing considerations for using nonstatin lipid-lowering therapy and proposes a practical approach for determining when to initiate nonstatin therapy.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
View Full Text
  1. Abhayjit Singh, MD
  1. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
  1. 6638-leslie-choLeslie S. Cho, MD⇑
  1. Section Head, Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
  2. Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Address:
    Leslie S. Cho, MD, Section Head, Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, JB-1, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; chol{at}ccf.org

ABSTRACT

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, with low-density lipoprotein (LDL) cholesterol being a causative risk factor. Though statins have a decades-long track record of efficacy and safety, nonstatin agents may be used to reduce LDL cholesterol as an adjunct or alternative to statin therapy. Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease. This review addresses the indications, evidence, and important prescribing considerations for using nonstatin lipid-lowering therapy and proposes a practical approach for determining when to initiate nonstatin therapy.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
View Full Text
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (1)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 1
1 Jan 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Abhayjit Singh, Leslie S. Cho
Cleveland Clinic Journal of Medicine Jan 2024, 91 (1) 53-63; DOI: 10.3949/ccjm.91a.23058

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Abhayjit Singh, Leslie S. Cho
Cleveland Clinic Journal of Medicine Jan 2024, 91 (1) 53-63; DOI: 10.3949/ccjm.91a.23058
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • INDICATIONS AND GOALS FOR LIPID-LOWERING THERAPY
    • SPECIFIC NONSTATIN THERAPIES
    • THERAPIES NOT ROUTINELY RECOMMENDED FOR LIPID MANAGEMENT
    • THERAPIES SPECIFIC TO PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    • CHOICE OF NONSTATIN THERAPY: A PRACTICAL APPROACH
    • FUTURE DIRECTIONS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Its a new year, looking back and looking forward
  • Google Scholar

More in this TOC Section

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
  • A practical guide for buprenorphine initiation in the primary care setting
Show more Current Drug Therapy

Similar Articles

Subjects

  • Cardiology
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire